Holen Sie sich die Stockscreener-App
8.15
6.32%
-0.55
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
80,000 stock options go to Ivana Rubino at ProMIS Neurosciences (PMN), exercisable at $9.37. - Stock Titan
Alzheimer’s drug data are expected in Q1 2027. ProMIS hires a former Biogen leader to shape market plans. - Stock Titan
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer - Carroll County Mirror-Democrat
ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - kalkine.ca
ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - Kalkine
ProMIS Neurosciences at Moody Capital conference: safety sets it apart By Investing.com - Investing.com Canada
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com Nigeria
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com Canada
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com India
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com UK
ProMIS Neurosciences (PMN) Edges Up 0.24% to $12.56 as Shares Consolidate Between Support and ResistanceChannel Breakout - siam.in
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September - Yahoo Finance
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Revenue Estimate Trend - vinanet.vn
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Positive Surprise Momentum - https://www.dars.gov.et/
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Book Value Growth - dars.gov.et
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Profit Guidance Range - dars.gov.et
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Earnings Forecast Report - www.dars.gov.et
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Diluted EPS Report - dars.gov.et
ProMIS Neurosciences PMN310 shows early Alzheimer's promise - scanx.trade
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEarnings Manipulation Risk - vinanet.vn
Q3 EPS Estimates for PMN Raised by Brookline Capital Markets - MarketBeat
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEPS Miss Report - dars.gov.et
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEPS Estimate Trend - dars.gov.et
ProMIS Neurosciences (PMN) Q2 2026 Update Highlights Strong Cash Position Amid High Valuation - GuruFocus
Maxim Group Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Momentum Breakout Ideas - vinanet.vn
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Call Wall - dars.gov.et
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Hedge Fund Favorites - dars.gov.et
Roth Capital initiates coverage on ProMIS Neurosciences with Buy rating - scanx.trade
PMN Maintained by Guggenheim -- Price Target Raised to $100 - GuruFocus
ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside - TradingView
Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
ProMIS Neurosciences (PMN): Great Point group reports 7.66% beneficial stake - Stock Titan
Guggenheim Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $100 - Moomoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ... By GuruFocus - Investing.com Canada
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlight - GuruFocus
Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33 - Moomoo
Promis Neurosciences Q2 Earnings Call Highlights - MarketBeat
Promis Neurosciences Q2 Earnings Call Highlights - TradingView
Promis Neurosciences Q2 Earnings Call Highlights - Yahoo Finance
PMN310 shows dose-dependent reduction of amyloid-beta oligomers - scanx.trade
ProMIS Neurosciences (PMN) Climbs 2.00% to $14.79, Approaching Key Resistance at $15.53Turnaround Stocks - vinanet.vn
PROMIS NEUROSCIENCES ($PMN) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com Canada
PMN: Interim phase I-B data for PMN310 showed no ARIA-E and strong biomarker signals, with cash runway through 2027 - TradingView
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com
ProMIS Neurosciences Q2 Results: Cash Runway Extends To 2027 - scanx.trade
Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ProMIS Neurosciences (PMN) gets 7.77% stake disclosure by Wellington fund - Stock Titan
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):